The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The effect of tetrathiomolybdate on endothelial progenitor cells in patients at high risk for breast cancer recurrence.
S. Jain
No relevant relationships to disclose
J. A. Cohen
No relevant relationships to disclose
M. M. Ward
No relevant relationships to disclose
J. O'Loughlin
No relevant relationships to disclose
M. Boeck
No relevant relationships to disclose
N. Wiener
No relevant relationships to disclose
E. Chuang
No relevant relationships to disclose
T. Cigler
No relevant relationships to disclose
A. Moore
No relevant relationships to disclose
D. Donovan
No relevant relationships to disclose
C. Lam
No relevant relationships to disclose
M. E. Cobham
No relevant relationships to disclose
S. E. Schneider
No relevant relationships to disclose
P. J. Christos
No relevant relationships to disclose
M. E. Lane
No relevant relationships to disclose
R. Baergen
No relevant relationships to disclose
V. Mittal
No relevant relationships to disclose
S. Rafii
No relevant relationships to disclose
L. T. Vahdat
Consultant or Advisory Role - Bristol-Myers Squibb; Eisai
Honoraria - Bristol-Myers Squibb; Eisai
Research Funding - Bristol-Myers Squibb; Celldex; Eisai; ImClone Systems; Novartis